Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Prasugrel

An antiplatelet medicine of the thienopyridine family, developed in Japan, that irreversibly blocks the P2Y12 receptor on platelets. Approved in 2009, it is used with acetylsalicylic acid in acute coronary syndromes treated with angioplasty. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.

Did you know?On its own it is inactive: esterases in the gut and liver first turn it into a thiolactone, then liver CYP enzymes convert it into the active metabolite that binds to platelets.

PrasugrelGo to the active ingredient →
PrasugrelActive ingredientPrasugrelCat. No. P-P171-001CAS 150322-43-3

EDQM standards 1

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.